MENU

Why the Sigma Healthcare Ltd share price has plunged 26% today

Unfortunately for its shareholders, the Sigma Healthcare Ltd (ASX: SIG) share price has been one of the worst performers on the local market this morning.

In early trade the shares of the company behind pharmacy chains including Amcal and Chemist King are down a massive 26% to 87.5 cents.

Why have they been crushed?

According to a shock release this morning, Sigma has advised that it has commenced legal proceedings against My Chemist/Chemist Warehouse Group (MC/CW).

At present Sigma acts as an exclusive supplier to MC/CW, but the latter has stated its intention to acquire certain products from an alternate wholesaler.

Management believes this to be a violation of its supply agreement. With its offers of mediation and binding arbitration rejected, the company had no choice but to initiate the legal proceedings.

What does this mean financially?

Asides from legal costs, management believes that if MC/CW goes ahead with its plan, it will impact Sigma’s earnings before interest and tax by between $5 million and $10 million per year. This is approximately 5.5% and 11% of its most recent full-year EBIT by my calculation.

As a result, management has advised that this and the weak retail environment could lead to a 5% drop in underlying earnings this year.

Should you buy the dip?

This decline has left its shares trading at just over 14x trailing earnings. Whilst this could arguably be a buying opportunity, I do feel that this is a worrying development.

With the current MC/CW supply agreement due to expire in June 2019, I would be very surprised to see it renewed following today’s announcement. This could leave an even bigger gap in its earnings in the future.

Whilst I have been a big fan of the company in the past, unfortunately I think this changes everything and makes it one to avoid now.

Instead of Sigma, investors might be better off looking elsewhere in the healthcare industry at companies such as Ramsay Health Care Limited (ASX: RHC) and Fisher & Paykel Healthcare Corp Ltd (ASX: FPH).

Alternatively, these stunning growth shares could be even better options for investors. Each has been growing like wildfire and looks to be great value still in my opinion.

Top 3 ASX Blue Chips To Buy In 2017

For many, blue chip stocks means stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2017."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

If you're expecting to see the likes of Commonwealth Bank, Telstra and Wesfarmers shares on this list, you'll be sorely disappointed. Not only are their dividends growing at a snail's pace, their profits are under pressure too due to the increasing competitive environment.

The contrast to these "new breed" blue chips couldn't be greater... especially the very real prospect of significant share price gains, something that's looking less likely from the usual blue chip suspects.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

HOT OFF THE PRESSES: My #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.